Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Dexcom (DXCM) Gets a Buy from Citi

Tipranks - Tipranks - Wed Apr 8, 6:26AM CDT

Citi analyst Joanne Wuensch reiterated a Buy rating on Dexcom today and set a price target of $84.00.

Easter Sale - 70% Off TipRanks

Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and GE Healthcare Technologies Inc. According to TipRanks, Wuensch has an average return of 2.3% and a 50.93% success rate on recommended stocks.

In addition to Citi, Dexcom also received a Buy from TipRanks – xAI’s xAi Medical – Devices in a report issued yesterday. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Dexcom (NASDAQ: DXCM).

See today’s best-performing stocks on TipRanks >>

Based on Dexcom’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.26 billion and a net profit of $267.3 million. In comparison, last year the company earned a revenue of $1.11 billion and had a net profit of $151.7 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).